Ludwig Institute for Cancer Research Limited

Other

Curis, Inc.

Peter Ten Dijke

Carl-Henrik Heldin

Kohei Miyazono

Petra Franzen

Hidetoshi Yamashita

Kuber T Sampath

Atsuhito Nakao

A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-&#x3b2;-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Antibodies which bind specifically to activin receptor like kinase 3

A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-beta-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Activin receptor-like kinase-1 proteins having serine-threonine kinase domains

Antibodies which bind specifically to activin receptor like kinases

Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptors particularly OP-1-binding cell surface receptors; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods and compositions for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods and compositions for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.

Methods of identifying morphogen receptor-binding analogs

Antibodies which bind specifically to activin receptor-like kinases

Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptors particularly OP-1-binding cell surface receptors ALK-2, ALK-3, and ALK-6; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAS; (4) methods and compositions for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods and compositions for identifying morphogen receptor binding analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic and experimental uses.

Morphogenic protein-specific cell surface receptors and uses therefor

The invention describes nucleic acids encoding the Smad7 protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.

Method for identifying compounds that affect Smad7 binding

The invention involves nucleic acid molecules which encode activin like kinases, expression vectors, and cell lines.

Isolated nucleic acid molecules which encode activin-receptor like kinases, expression vectors and cells containing these

A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-&bgr;-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.

Activin receptor-like kinases, proteins having serine threonine kinase domains and polynucleotides encoding same

The invention involves three members of the activin like receptor kinase family, and the nucleic acids encoding these.

Activin like receptor--Isolated kinase proteins ALK-2, ALK-4, ALK-5, and nucleic acid molecules encoding them

The invention relates to two members of the receptor family referred to as activin-like kinases. These two members are referred to as ALK-3 and ALK-6. The proteins have activin/TGF-&bgr; type I receptor functionality, and may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain V1B, and/or a GTKRYM sequence in subdomain VIII.

Growing community of inventors

Uppsala, Sweden

Peter Ten Dijke